Press "Enter" to skip to content

Without significant adverse outcomes reported.

All patients in study clear parasite that triggers African sleeping sickness Immtech International has announced that 30 patients participating in the concluded Stage IIb extended dose program arm of its clinical trial of DB289 for treating African sleeping sickness cleared the parasite that triggers African sleeping sickness within the treatment period, without significant adverse outcomes reported. The medical investigators shall continue to monitor the patients for re-occurrence of the condition at 3, 6, and 12 a few months. The study was executed at two sites in the Democratic Republic of the Congo-Maluku and Vanga .

Particularly, Long reminds that all international adoptees be screened upon arrival in THE UNITED STATES for latent tuberculosis infection by using the Mantoux tuberculin epidermis test. Children with positive tuberculin pores and skin test results or who’ve symptoms suggestive of tuberculosis ought to be examined for evidence of active disease and have a upper body radiograph performed. Children with latent tuberculosis infection or active tuberculosis disease should be treated relative to the American tuberculosis criteria. If the child was previously within an orphanage or children’s house, the constant state tuberculosis program should, in discussion with the adoptive family members, notify the orphanage or home, and also the adoptive agency.. All small children adopted from outside North America should be screened for TB University of Alberta experts stress that children adopted from outdoors North America ought to be screened for tuberculosis.